Back to results
US 2024/0181027 A1Published application
Canine lyme disease vaccine
AssigneeIntervet Inc.
InventorsRhonda LaFleur, Jennifer C. Dant, Mark A. Mogler, Steven M. Callister, Zhichang Xu
Life of this patent
Estimating the term…
Abstract
The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.
Claims21
An immunogenic composition comprising two or more alphavirus RNA replicon particles each individually encoding one or more Borrelia burgdorferi antigens or antigenic fragments thereof;
- wherein one alphavirus RNA replicon particle encodes a one or more Borrelia burgdorferi outer surface protein A (OspA) or an antigenic fragment thereof, and wherein another alphavirus RNA replicon particle encodes one or more Borrelia burgdorferi outer surface protein C (OspC) or an antigenic fragment thereof.
An immunogenic composition comprising an alphavirus RNA replicon particle that encodes two or more Borrelia burgdorferi antigens;
- wherein at least one Borrelia burgdorferi antigen is an outer surface protein A (OspA) or an antigenic fragment thereof;
- and wherein at least one other Borrelia burgdorferi antigen is an outer surface protein C (OspC) or an antigenic fragment thereof.
canceled
canceled
Dependencies are inferred from the claim text.